Johnson&Johnson

Johnson & Johnson Health Care Systems Inc.
1000 US Highway 202 South
Raritan NJ 08869 United States

To Whom It May Concern,

This email provides important information about Johnson & Johnson's (J&J) upcoming implementation of the "Maximum Fair Price" ("MFP") effectuation requirements. "MFP" effectuation is a government mandate under the Inflation Reduction Act (IRA) that must be applied to select medications under Medicare Part D. We recognize your organization's importance in delivering care and appreciate your partnership in ensuring compliance and minimizing disruptions.

Key Information and Timeline
As part of J&J's continued commitment to compliance with the IRA, we are preparing to implement the "Maximum Fair Price" ("MFP") effectuation requirements, which will take effect on **January 1, 2026**.

What You Need to Know About the "MFP": Claims and Payment Processing

Under the IRA, the "MFP" is a mandatory price cap that must be applied to certain medications covered under Medicare Part D. Starting in 2026, J&J will offer the "MFP" for selected products, XARELTO®, STELARA®, and USTEKINUMAB.

According to guidance from the Centers for Medicare & Medicaid Services (CMS), manufacturers must transmit "MFP" refunds to dispensing entities within 14 days of receiving all required and accurate claim data from the Medicare Transaction Facilitator (MTF) Data Module. The MTF is a third-party administrator responsible for processing "MFP"-related claims data and overseeing compliance.

All manufacturers will use the same MTF for data transmission. J&J will adhere to CMS's 14-day payment timeline upon receipt of valid claims data and will leverage the MTF Payment Module (PM) to facilitate the payment process.

What "MFP" Effectuation Means for Dispensing Entities

As we work to implement "MFP" effectuation, we recognize the crucial role that your organization plays in delivering care. Your collaboration is essential for ensuring compliance and minimizing disruptions.

As part of our "MFP" effectuation implementation efforts, J&J will:

- Encourage timely and accurate claim identification.
- Maintain open lines of communication with your team and designated contacts.

If you have any questions or need additional information, please review J&J's "MFP" Implementation Plan for IPAY 2026: https://innovativemedicine.jnj.com/us/authorized-distributors/policies.

Thank you for your partnership and continued trust as we implement this important policy change. We look forward to working with you throughout this implementation period.